New drug shows promise against stubborn digestive cancers
NCT ID NCT05628857
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tested an experimental drug called RC108 in 29 adults with advanced digestive system cancers that have a specific marker (c-Met). The goal was to see if the drug could shrink tumors or stop them from growing. Participants received the drug and were monitored for side effects and how well the drug worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hopspital
Beijing, Beijing Municipality, 000000, China
Conditions
Explore the condition pages connected to this study.